Early treatment for diabetes caused by cancer immunotherapy
Treatments studied
Part of Hormones & metabolism clinical trials.
This study tests whether a drug called infliximab can help preserve insulin-making cells in people who develop diabetes after receiving immune checkpoint inhibitor (ICI) cancer treatment. It aims to improve blood sugar control and reduce the need for insulin.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are currently receiving or have recently received immune checkpoint inhibitor (ICI) cancer therapy.
- You have been diagnosed with new-onset diabetes or a significant worsening of blood sugar control after starting ICI treatment.
- You have not been on insulin for diabetes before starting ICI therapy.
- You have adequate organ function and are generally in good health (able to perform daily activities).
- You agree to use effective birth control if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug that may help preserve the body's ability to make insulin in people with type 1 diabetes. It aims to slow the progression of the disease and reduce the need for insulin injections.
This study looks at how immunotherapy affects the quality of life of cancer patients who also have diabetes. It aims to understand and improve their overall well-being during treatment.
This trial studies whether infliximab can treat stomach inflammation in the colon (colitis) or frequent diarrhea caused by immune checkpoint cancer drugs. It aims to improve symptoms safely for adults with certain solid cancers.
This study tests whether infliximab can treat kidney damage caused by immune checkpoint inhibitor cancer therapy. It aims to see if this medication helps patients recover kidney function after injury from their cancer treatment.
This study looks at how common medicines might interact with immunotherapy (a treatment that helps your immune system fight cancer). Participation could help doctors learn how to better manage side effects and dosing for patients on these treatments.
This trial tests immunotherapy drugs (checkpoint inhibitors) that are not officially approved for your specific cancer but may help fight it. The goal is to see if these off-label treatments are safe and effective for a wide range of cancer types.
Hear when a new Pilot Study trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.